Clinical Trial Detail

NCT ID NCT02293980
Title A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Peloton Therapeutics, Inc.
Indications

clear cell renal cell carcinoma

Therapies

PT2385

Nivolumab + PT2385

Age Groups: adult

No variant requirements are available.